CAST and beyond. Implications of the Cardiac Arrhythmia Suppression Trial. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.
Instituto di Clinica Medica II, Universitá di Milano, Italy.
M
M
Akhtar
G
G
Breithardt
A J
AJ
Camm
P
P
Coumel
M J
MJ
Janse
R
R
Lazzara
R J
RJ
Myerburg
P J
PJ
Schwartz
A L
AL
Waldo
H J
HJ
Wellens
D000813:Anilides / Q000009:adverse effects / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D004311:Double-Blind Method; D016700:Encainide; D005424:Flecainide / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D016293:Moricizine; D015337:Multicenter Studies as Topic; D010640:Phenothiazines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic
D000813:Anilides; D000889:Anti-Arrhythmia Agents; D010640:Phenothiazines; D016293:Moricizine; D005424:Flecainide; D016700:Encainide